地特胰岛素联合瑞格列奈治疗初诊断2型糖尿病的临床疗效观察

The clinical efficacy of insulin detemir in combination with repaglinide for treating newly diagnosed type 2 diabetes

目的:观察地特胰岛素联合瑞格列奈治疗初发2型糖尿病的临床疗效。方法:30例初次诊断的2型糖尿病患者采用地特胰岛素和瑞格列奈联合治疗,观察治疗12周前后的空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)、BMI变化。结果:与治疗前比较,治疗12周后患者的FBG、2hPG和HbA1C均明显降低(P<0.05),无夜间低血糖发生。治疗前后体重无明显增加。结论:地特胰岛素联合瑞格列奈治疗初诊断2型糖尿病,血糖达标率高,低血糖发生率低,体重增加不明显。

Objective： To investigate the clinical efficacy of insulin detemir in combination with repaglinide for treating newly diagnosed type 2 diabetes.Methods：Thirty newly diagnosed type 2 diabetes patients were received insulin detemir injection in combination with repaglinide.After 12 weeks treatment,the patients were observed how much indices of fasting blood glucose（FBG）,2-hour postprandial blood glucose（2hPG）,glycated hemoglobin（HbA1C） and body mass index（BMI）changed.Results：Compared with before treatment,FBG,2hPG and HbA1C were significantly decreased after 12 weeks of treatment（P0.05）,and there was no nocturnal hypoglycemia.There was no significant difference in BMI between before and after treatment.Conclusion：The treatment of detemir insulin in combination with repaglinide could efficiently improve diabetes care in newly diagnosed type 2 diabetes patients,with a lower incidence of hypoglycemia and no obvious increasing of body weight.